This study is testing a medicine called empasiprubart given through an IV for people with generalized myasthenia gravis (gMG). This is a condition where your immune system mistakenly attacks your body, causing muscle weakness. You may be able to join if you are 18 or older, have gMG that is confirmed by a specific blood test (AChR-Ab seropositive), and meet certain health criteria. The main goal is to see how safe empasiprubart is by tracking any side effects over about 12 weeks. This study is part of a larger effort to find better treatments for gMG. The current status of recruitment is unclear.

Study design

This is an interventional study that plans to enroll 40 participants. Participants will be randomly assigned to receive either empasiprubart IV or a placebo IV, and later all will receive efgartigimod PH20 SC PFS.

What's involved

The study duration for each participant is approximately up to 45 weeks. You would receive intravenous infusions of empasiprubart or placebo, and later subcutaneous injections of efgartigimod PH20.

Compensation

Not stated in the trial record.

Follow-up

The primary safety endpoints are measured up to 12 weeks after treatment. The total study duration for each participant is approximately up to 45 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.